Valsartan/Hydrochlorothiazide
Brand name: Valsartan-Hydrochlorothiazide
Rank #359 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$27.5M
Total Cost
510,583
Total Claims
$27.5M
Total Cost
19,091
Prescribers
$54
Cost per Claim
64,459
Beneficiaries
1,311,844
30-Day Fills
$1,440
Avg Cost/Provider
27
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$27.5M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $27.5M total
Top Prescribers of Valsartan/Hydrochlorothiazide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Rafael Rodriguez | Internal Medicine | Jackson Heights, NY | 470 | $41K |
| 2 | Mikhail Chilingaryan | General Practice | Pittsburgh, PA | 590 | $32K |
| 3 | Mohammad Chaudhry | Internal Medicine | Union City, NJ | 393 | $31K |
| 4 | Jacob Webster | Internal Medicine | Mobile, AL | 410 | $30K |
| 5 | Jeffrey Tauth | Cardiology | Hot Springs National Park, AR | 473 | $26K |
| 6 | Ricardo Cigarroa | Interventional Cardiology | Laredo, TX | 447 | $24K |
| 7 | Manuel Franco | Internal Medicine | Miami, FL | 519 | $24K |
| 8 | Hani Salti | Cardiology | Vernon Hills, IL | 385 | $24K |
| 9 | Branislav Schifferdecker | Interventional Cardiology | Oklahoma City, OK | 342 | $23K |
| 10 | Sachin Kumar Amruthlal Jain | Cardiology | Yonkers, NY | 244 | $22K |
| 11 | Joseph Stella | Interventional Cardiology | Mokena, IL | 309 | $22K |
| 12 | James Hall | Cardiology | Union City, TN | 394 | $22K |
| 13 | Arutyun Topsakalyan | General Practice | Glendale, CA | 608 | $21K |
| 14 | Fernando Segovia | Interventional Cardiology | Edgewater, NJ | 296 | $19K |
| 15 | Durga Madala | Cardiology | San Jose, CA | 404 | $19K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 356 | Aflibercept (Eylea) | $28.0M | 10,899 |
| 357 | Fostemsavir Tromethamine (Rukobia) | $27.8M | 3,094 |
| 358 | Colchicine (Colchicine) | $27.5M | 314,046 |
| 359 | Valsartan/Hydrochlorothiazide (Valsartan-Hydrochlorothiazide) | $27.5M | 510,583 |
| 360 | Ropinirole Hcl (Ropinirole Hcl) | $27.5M | 1,204,903 |
| 361 | Trifluridine/Tipiracil Hcl (Lonsurf) | $27.3M | 2,430 |
| 362 | Memantine Hcl/Donepezil Hcl (Namzaric) | $27.2M | 46,134 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology